Rafal C.
- Country
- Poland
- Department
- NA
Research Overview
- B7981040 - A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO
- Efficacy and Safety Evaluation of JNJ-77242113 Versus Placebo and Deucravacitinib in Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Controlled Trial
- Efficacy and Safety Evaluation of JNJ-77242113 in Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Data & Insights
Has run more than one trial at 188 of 367 partner sites.
Specializations
Psoriasis Management
Specialized in investigating innovative treatments for moderate-to-severe plaque psoriasis, including both widespread presentation and cases affecting special areas of the body.
- Plaque psoriasis therapeutics
- Long-term disease management
- Special area manifestations
Focuses on evaluating novel therapeutic approaches for comprehensive psoriasis control.
Vitiligo Treatment
Dedicated to advancing treatment options for nonsegmental vitiligo, with particular emphasis on systemic therapeutic approaches and long-term management strategies.
- Novel vitiligo interventions
- Systemic treatment protocols
- Treatment effectiveness assessment
Explores multiple therapeutic compounds for vitiligo management.
Dermatological Conditions
Expert in treating various dermatological conditions including chronic hand eczema, atopic hand eczema, and alopecia areata.
- Hand eczema therapeutics
- Alopecia areata management
- Inflammatory skin conditions
Specializes in developing treatment approaches for challenging dermatological presentations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.